High‐dose chemotherapy with stem cell rescue in the primary treatment of metastatic and pelvic osteosarcoma: Final results of the ISG/SSG II study

医学 异环磷酰胺 卡铂 依托泊苷 化疗 外科 环磷酰胺 骨肉瘤 顺铂 阿霉素 肿瘤科 内科学 病理
作者
Kjetil Boye,Adalberto Brach del Prever,Mikael Eriksson,Gunnar Sæter,Amelia Tienghi,Paula Lindholm,Franca Fagioli,Sigmund Skjeldal,Stefano Ferrari,Kirsten Sundby Hall
出处
期刊:Pediatric Blood & Cancer [Wiley]
卷期号:61 (5): 840-845 被引量:54
标识
DOI:10.1002/pbc.24868
摘要

BACKGROUND: Patients with metastatic osteosarcoma at diagnosis or axial primary tumors have a poor prognosis. The aim of the study was to evaluate the feasibility and efficacy of intensified treatment with high-dose chemotherapy (HDCT) and stem cell rescue in this group. METHODS: From May 1996 to August 2004, 71 patients were included in a Scandinavian-Italian single arm phase II study. Preoperative chemotherapy included methotrexate, doxorubicin, cisplatin and ifosfamide, and postoperative treatment consisted of two cycles of doxorubicin, one cycle of cyclophosphamide and etoposide and two courses of high-dose etoposide and carboplatin with stem cell rescue. RESULTS: Twenty-nine patients (43%) received two courses and 10 patients (15%) received one course of HDCT. HDCT was associated with significant toxicity, but no treatment-related deaths were recorded. Fourteen patients (20%) had disease progression before completion of the study protocol, and only 29/71 patients (41%) received the full planned treatment. Median event-free survival (EFS) was 18 months, and estimated 5-year EFS was 27%. Median overall survival (OS) was 34 months, and estimated 5-year OS was 31%. When patients who did not receive HDCT due to disease progression were excluded, there was no difference in EFS (P = 0.72) or OS (P = 0.49) between patients who did or did not receive HDCT. CONCLUSIONS: The administration of high-dose chemotherapy with stem cell rescue was feasible, but associated with significant toxicity. Patient outcome seemed comparable to previous studies using conventional chemotherapy. We conclude that HDCT with carboplatin and etoposide should not be further explored as a treatment strategy in high-risk osteosarcoma.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
沐木发布了新的文献求助30
2秒前
yrz完成签到,获得积分20
3秒前
斯文败类的应助被xwx采纳,获得10
4秒前
徐丹枫发布了新的文献求助10
4秒前
4秒前
乌龙茶发布了新的文献求助10
4秒前
我是老大的应助被科研通管家采纳,获得10
4秒前
深情安青的应助被科研通管家采纳,获得10
5秒前
5秒前
FashionBoy的应助被科研通管家采纳,获得50
5秒前
情怀的应助被科研通管家采纳,获得10
5秒前
Hase的应助被科研通管家采纳,获得30
5秒前
秋风的应助被科研通管家采纳,获得10
5秒前
华仔的应助被科研通管家采纳,获得10
5秒前
酷波er的应助被科研通管家采纳,获得10
5秒前
CipherSage的应助被科研通管家采纳,获得20
6秒前
勤奋一一的应助被科研通管家采纳,获得10
6秒前
研友_VZG7GZ的应助被科研通管家采纳,获得10
6秒前
6秒前
王英霖的应助被科研通管家采纳,获得20
6秒前
秋风的应助被科研通管家采纳,获得20
6秒前
syvshc的应助被科研通管家采纳,获得10
6秒前
李爱国的应助被科研通管家采纳,获得10
6秒前
科研通AI2S的应助被科研通管家采纳,获得10
7秒前
Luna666完成签到,获得积分10
7秒前
乐乐的应助被科研通管家采纳,获得10
7秒前
7秒前
wanci的应助被科研通管家采纳,获得50
7秒前
7秒前
丁亦竹发布了新的文献求助100
8秒前
能干灯泡发布了新的文献求助10
9秒前
赘婿的应助被观山青采纳,获得10
9秒前
传奇3的应助被平常的路人采纳,获得10
9秒前
我家电脑完成签到 ,获得积分10
10秒前
11秒前
科目三的应助被XPR采纳,获得10
11秒前
eeeee完成签到,获得积分10
12秒前
木子发布了新的文献求助10
13秒前
15秒前
memebao完成签到,获得积分10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181767
求助须知:如何正确求助?哪些是违规求助? 9571480
关于积分的说明 21818225
捐赠科研通 7778030
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479598